Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on Dollarama, Raises Price Target to C$93

RBC Capital analyst Irene Nattel maintains Dollarama (TSX:DOL) with a Outperform and raises the price target from C$81 to C$93.

byBenzinga Newsdesk

August 31, 2022

1 minute read

RBC Capital analyst Irene Nattel maintains Dollarama (TSX:DOL) with a Outperform and raises the price target from C$81 to C$93.

Merck’s Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients

By Vandana Singh

March 7, 11:22 AM

Merck & Co Inc (NYSE: MRK) announced data from Phase 3 KEYNOTE-716 trial of Keytruda (pembrolizumab) as adjuvant treatment for patients with resected stage IIB and IIC melanoma.

MRK

Barclays Initiates Coverage On XPeng with Overweight Rating

By Benzinga Newsdesk

February 8, 7:30 AM

Barclays analyst Jiong Shao initiates coverage on XPeng (NYSE:XPEV) with a Overweight rating.

XPEV

Analyst Ratings

What 4 Analyst Ratings Have To Say About VICI Properties

By Benzinga Insights

October 4, 10:32 AM

Analysts have provided the following ratings for VICI Properties (NYSE:VICI) within the last quarter:

VICI

Raymond James Maintains Outperform on Capital Southwest, Lowers Price Target to $26

By Benzinga Newsdesk

May 25, 4:38 AM

Raymond James analyst Robert Dodd maintains Capital Southwest (NASDAQ:CSWC) with a Outperform and lowers the price target from $28.5 to $26.

CSWC

RBC Capital Maintains Outperform on Dollarama, Raises Price Target to C$93

Related Posts

Merck’s Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients

Barclays Initiates Coverage On XPeng with Overweight Rating

What 4 Analyst Ratings Have To Say About VICI Properties

Raymond James Maintains Outperform on Capital Southwest, Lowers Price Target to $26